Hepatitis

Hepatitis B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Fri, 21 Oct 2022 16:02:05 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Drugs In Development, 2022, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and...

$2,500.00

Hepatitis B Virus Surface Antigen (HBsAg) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 13:33:41 +0000

Summary

Hepatitis B Virus Surface Antigen (HBsAg) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Hepatitis B Virus Surface Antigen (HBsAg) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Hepatitis B Virus Surface Antigen (HBsAg) targeted therapeutics development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter str...

$2,500.00

Autoimmune Hepatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 12:37:01 +0000

Summary

Autoimmune Hepatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Autoimmune Hepatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Autoimmune Hepatitis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, co...

$2,000.00

Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepatitis B Virus Ribonuclease H or EC 2.7.7.7 or EC 2.7.7.49 or EC 3.1.26.4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Playe

Tue, 12 Jul 2022 14:45:37 +0000

Summary

Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepatitis B Virus Ribonuclease H or EC 2.7.7.7 or EC 2.7.7.49 or EC 3.1.26.4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepatitis B Virus Ribonuclease H or EC 2.7.7.7 or EC 2.7.7.49 or EC 3.1.26.4) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepat...

$2,500.00

Hepatitis C Virus Envelope Protein E1 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

Tue, 12 Jul 2022 14:45:37 +0000

Summary

Hepatitis C Virus Envelope Protein E1 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Hepatitis C Virus Envelope Protein E1 targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Hepatitis C Virus Envelope Protein E1 targeted therapeutics development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to g...

$2,500.00

Hepatitis E Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Tue, 12 Jul 2022 14:45:37 +0000

Summary

Hepatitis E Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Hepatitis E pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis E, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, ...

$2,000.00

U.S. Hepatitis Vaccines Market – Growth, Demand, Trends, Opportunity, Forecasts (2021 – 2027)

Mon, 23 May 2022 12:18:53 +0000

The United States hepatitis vaccines market is projected to boost over the forecast period of 2021 to 2027. This new market report provides a comprehensive analysis of the fast-evolving, high-growth U.S hepatitis vaccines market. The report offers the foremost up-to-date industry data on the specific market situation and future outlook for the U.S. hepatitis vaccines market. The report provides historical market data for 2015 – 2020, and forecasts from 2021 till 2027. The report additionally provides a detailed evaluation of the leading 6 key marketed hepatitis vaccines market assessments, data from 2015 to 2020, and forecasts to 2027. Additionally, this up-to-date report describes the latest features reimbursement pattern and offers a clear view of the regulatory framework of the United States hepatitis vaccines market. An all-inclusive examination has been done on the pricing trends and analysis of the hepatitis vaccines in the United States. The report also offers detailed information about the recruiting clinical trials statement by phase, trial status, study sponsor name, ...

$1,500.00

Hepatitis Drugs Markets in China

Tue, 12 Apr 2022 15:07:33 +0000

China's demand for Hepatitis Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2011, 2016 and 2021) and long-term forecasts through 2026 and 2031 are presented. Major producers in China are profiled. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments’ industry bureaus, industry publications, and our in-house databases. Interviews are conducte...

$4,000.00

Hepatitis Drugs Industry Forecasts - China Focus

Tue, 12 Apr 2022 15:07:33 +0000

This study focuses on China’s Hepatitis Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering from minimal innovation...

$1,800.00

Hepatitis Drugs Companies in China

Tue, 12 Apr 2022 15:07:33 +0000

This study focuses on China’s Hepatitis Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering ...

$1,800.00

Hepatitis B (Infectious Disease) - Drugs in Development, 2021

Tue, 12 Oct 2021 15:07:55 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Drugs In Development, 2021, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule...

$2,500.00

Hepatitis C - Pipeline Insight, 2021

Fri, 19 Mar 2021 14:59:26 +0000

DelveInsight’s, “Hepatitis C - Pipeline Insight, 2021,” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Hepatitis C pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Hepatitis C Understanding Hepatitis C: Overview Hepatitis C is a liver infection caused by the hepatitis C virus. Hepatitis C can range from a mild illness lasting a few weeks to a serious, long-term illness. The hepatitis C virus (HCV) spreads through contaminated blood. The hepatitis C virus is a blood borne virus, the most common modes of infection are through exposure to small quantities of blood. This may happen through injection drug use, unsafe injection practices, unsafe health care, transfusion of unscreened blood and blood products, and sexual practices that lead to exposure to blood. Hepatitis C...

$2,500.00

Chronic Hepatitis B Virus Market Insight, Epidemiology and Market Forecast -2030

Wed, 14 Oct 2020 15:56:15 +0000

DelveInsight’s ‘Chronic Hepatitis B Virus (CHB) - Market Insights, Epidemiology and Market Forecast —2030’ report delivers an in-depth understanding of the CHB, historical and forecasted epidemiology as well as the CHB market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The CHB market report provides current treatment practices, emerging drugs, CHB market share of the individual therapies, current and forecasted CHB market size from 2017 to 2030 segmented by seven major markets. The Report also covers current CHB treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market. Geography Covered • The United States • EU5 (Germany, France, Italy, Spain and the United Kingdom) • Japan Study Period: 2017–2030 Chronic Hepatitis B Virus (CHB): Disease Understanding and Treatment Algorithm Chronic Hepatitis B Virus Overview Hepatitis B is the most common serious liver infection in the world. It is caused by the hep...

$6,950.00

Alcoholic Hepatitis - Pipeline Review, H1 2020

Thu, 07 May 2020 13:39:47 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcoholic Hepatitis - Pipeline Review, H1 2020, provides an overview of the Alcoholic Hepatitis (Gastrointestinal) pipeline landscape.

Alcoholic hepatitis is an inflammation of the liver. It is typically caused by excessive alcohol consumption over a long period of time. Symptoms include changes in appetite, dry mouth, weight loss, yellowing of the skin or eyes (jaundice), fever and fatigue. Risk factors include alcohol use, obesity and genetic factors. Treatment includes corticosteroids and liver transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alcoholic Hepatitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological...

$2,000.00

Hepatitis C - Pipeline Review, H1 2020

Thu, 07 May 2020 13:39:47 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C - Pipeline Review, H1 2020, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.

Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis C - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectio...

$2,000.00

Hepatitis D - Pipeline Review, H1 2020

Thu, 07 May 2020 13:13:49 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D - Pipeline Review, H1 2020, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.

Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis D - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutic...

$2,000.00

Hepatitis A - Pipeline Review, H1 2020

Thu, 07 May 2020 13:13:49 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis A - Pipeline Review, H1 2020, provides an overview of the Hepatitis A (Infectious Disease) pipeline landscape.

Hepatitis A is inflammation of the liver caused by hepatitis A virus. Symptoms include fatigue, nausea and vomiting, inflammation of the liver, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes (jaundice). Risk factors include weakened immune system and use injected or non-injected illicit drugs. Treatment includes antiemetics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis A - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hepatitis A (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its...

$2,000.00

Alcoholic Hepatitis - Pipeline Review, H2 2019

Wed, 11 Dec 2019 11:13:09 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcoholic Hepatitis - Pipeline Review, H2 2019, provides an overview of the Alcoholic Hepatitis (Gastrointestinal) pipeline landscape.

Alcoholic hepatitis is an inflammation of the liver. It is typically caused by excessive alcohol consumption over a long period of time. Symptoms include changes in appetite, dry mouth, weight loss, yellowing of the skin or eyes (jaundice), fever and fatigue. Risk factors include alcohol use, obesity and genetic factors. Treatment includes corticosteroids and liver transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alcoholic Hepatitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological...

$2,000.00

Hepatic Encephalopathy - Pipeline Review, H1 2019

Tue, 26 Mar 2019 12:29:57 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy - Pipeline Review, H1 2019, provides an overview of the Hepatic Encephalopathy (Gastrointestinal) pipeline landscape.

Hepatic encephalopathy is a worsening of brain function that occurs when the liver is no longer able to remove toxic substances in the blood. Symptoms include disorientation, drowsiness or confusion, change in sleep patterns, slurred speech and agitation, excitement, or seizures (occur rarely). The predisposing factors include gastrointestinal bleeding, increased protein intake, renal dysfunction with azotemia, constipation (due to increased nitrogen load), drugs (particularly sedatives and diuretics) and hypoxia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatic Encephalopathy - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy (Gastrointestinal), complete with analysis by stage o...

$2,000.00

Alcoholic Hepatitis Global Clinical Trials Review, H2, 2018

Fri, 07 Dec 2018 15:32:55 +0000

Summary

GlobalData's clinical trial report, “Alcoholic Hepatitis Global Clinical Trials Review, H2, 2018" provides an overview of Alcoholic Hepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Alcoholic Hepatitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain...

$2,500.00

Hepatitis D - Pipeline Review, H2 2018

Thu, 29 Nov 2018 13:32:16 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D - Pipeline Review, H2 2018, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.

Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis D - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutic...

$2,000.00

Hepatitis A - Pipeline Review, H2 2018

Thu, 29 Nov 2018 13:32:16 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis A - Pipeline Review, H2 2018, provides an overview of the Hepatitis A (Infectious Disease) pipeline landscape.

Hepatitis A is inflammation of the liver caused by hepatitis A virus. Symptoms include fatigue, nausea and vomiting, inflammation of the liver, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes (jaundice). Risk factors include weakened immune system and use injected or non-injected illicit drugs. Treatment includes antiemetics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis A - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hepatitis A (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its...

$2,000.00

Hepatitis E - Pipeline Review, H1 2018

Mon, 03 Sep 2018 14:10:02 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis E - Pipeline Review, H1 2018, provides an overview of the Hepatitis E (Infectious Disease) pipeline landscape.

Hepatitis E is a serious disease caused by the hepatitis E virus (HEV). The virus targets the liver. Symptoms include yellowing of the skin, dark urine, fever, fatigue, joint pain, nausea, a loss of appetite, pain in the abdomen. It is caused by drinking water contaminated by fecal matter.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis E - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hepatitis E (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

...

$2,000.00

Hepatitis C: Competitive Landscape to 2026

Mon, 06 Aug 2018 15:35:30 +0000

Summary

Hepatitis C is a liver infection caused by the hepatitis C virus (HCV), a small enveloped RNA virus. If left untreated, chronic infection can result in fibrosis, cirrhosis, hepatocellular carcinoma, and eventually death. HCV is spread primarily by exposure to infected blood.

This report provides an assessment of the pipeline, clinical, and commercial landscape of hepatitis C. Overall, GlobalData expects next-generation direc-acting antiviral (DAA) regimens to drive growth, with opportunities for new entrants residing primarily in emerging markets (Brazil and China) over the next decade (2016-2026).

Scope

This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include -
- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
- Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytic...

$3,495.00

Alcoholic Hepatitis Global Clinical Trials Review, H1, 2017

Fri, 12 May 2017 15:24:23 +0000

Summary

GlobalData's clinical trial report, “Alcoholic Hepatitis Global Clinical Trials Review, H1, 2017" provides an overview of Alcoholic Hepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Alcoholic Hepatitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain...

$2,500.00